Ranbaxy temporarily ceases manufacturing of atorvastatin following recall

Following the announcement of a voluntary recall of atorvastatin on Nov. 9, Ranbaxy Pharmaceuticals has temporarily halted manufacturing of the drug, according to an FDA statement. The recall was initiated due to possible contamination with glass particles.

The manufacturer has not currently received any reports of patient harm due to the glass particulates that may be in the 41 lots affected by the recall. Based on information from Ranbaxy and from the FDA’s initial assessment, the possibility of adverse events related to the recalled product appears to be low and would be temporary, according to the statement.

The FDA does not anticipate a shortage of atorvastatin, but will continue to monitoring the situation and collaborating with other manufacturers of the drug to ensure adequate market supply.

For a list of the lots included in the recall, see the press release from Ranbaxy.